Panel reports on gene therapy death

The cause of death of a patient in a July gene therapy trial was a massive fungal infection, according to an initial autopsy report presented at the NIH Recombinant DNA Advisory Committee meeting today (September 17). Preliminary evidence suggests that adeno-associated virus (AAV), the vector which delivered the therapy, was not to blame, experts said. The subject, Jolee Mohr, 36, died from widespread histoplasmosis accompanied by a hematoma that ruptured her organs, according John Hart, a pathologist at the University of Chicago who presented the autopsy results. At the time of her death, she had disseminated histoplasmosis in several organs of her body. Although it is highly unlikely that AAV was responsible for the infection, further tests looking for presence of the expressed protein are needed to conclusively rule out the possibility, according to speakers at the panel."It seems that systemic histoplasmosis was a major contributing event that led to a lot of things that went downhill," Mark Kay, at the Stanford University School of Medicine, told The Scientist. "I don't know how people will spin it, but sounds to me like this was bad result of a medical therapy that probably was unrelated to gene therapy." Mohr was part of Targeted Genetics' phase I/II clinical trial of tgAAC94, an adeno-associated virus (AAV) vector to treat inflammatory arthritis by inhibiting tumor necrosis factor at joints. Beginning July 2, she reported a fever, nausea and vomiting and was admitted to the hospital seven days later. She was transferred to the University of Chicago Medical Center several days later. A CAT scan revealed a massive retroperitoneal hemorrhage which eventually punctured the lungs and displaced the organs in the abdominal cavity. The FDA halted the trial once the adverse effect had been reported by the clinical trial group. Mohr died on July 24. Since the death of Jesse Gelsinger, a patient in a gene therapy trial in 1999, the field has been dogged by setbacks. Carol Kauffman, from the University of Michigan, a speaker on the panel, said that in addition to histoplasmosis, the autopsy also revealed severe sepsis and other symptoms often seen in AIDS patients. There have been 40 known cases of histoplasmosis in patients undergoing anti-tumor necrosis factor therapy.Andrea Gawrylewski mail@the-scientist.comLinks within this article:A. Gawrylewski, "Company: Fungus likely caused gene trial death," The Scientist, September 14, 2007. http://www.the-scientist.com/blog/display/53589/C. Shekhar, "Gene therapy trial on hold," The Scientist, July 31, 2007. http://www.the-scientist.com/news/display/53453/The agenda for September 17 meeting http://www4.od.nih.gov/oba/RAC/meetings/Sep2007/DraftAgenda_sep2007.pdf
Mark Kay http://kaylab.stanford.edu/Pages/Personnel/mark.htmlCarol Kauffman http://www2.med.umich.edu/departments/infectious/index.cfm?fuseaction=infectious.facultyBio&individual_id=16022&um_department=Internal%20Medicine

Panel reports on gene therapy death

The Scientist ARCHIVES

Become a Member of

Meet the Author

Andrea Gawrylewski

Related Research Resources

Study Confirms Safety of Genetically Modified T Cells

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Making Real-Time PCR More Straightforward

Characterizing Immune Memory to COVID-19 Vaccination

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Products

Product News

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

Agilent BioTek Cytation C10 Confocal Imaging Reader